Ascendiant has revised its price target for Lucid Diagnostics (LUCD, Financial), raising it from $7.50 to $7.75, while maintaining a Buy rating on the stock. This adjustment follows the company's Q1 results. The firm anticipates significant growth for Lucid Diagnostics by 2025, suggesting that the stock could experience substantial price increases in the future.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Lucid Diagnostics Inc (LUCD, Financial) is $3.75 with a high estimate of $7.50 and a low estimate of $2.00. The average target implies an upside of 207.38% from the current price of $1.22. More detailed estimate data can be found on the Lucid Diagnostics Inc (LUCD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Lucid Diagnostics Inc's (LUCD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Lucid Diagnostics Inc (LUCD, Financial) in one year is $4.69, suggesting a upside of 284.43% from the current price of $1.22. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Lucid Diagnostics Inc (LUCD) Summary page.
LUCD Key Business Developments
Release Date: May 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Lucid Diagnostics Inc (LUCD, Financial) performed 3,034 e-cigar tests in Q1, reaching the upper end of their target range.
- The company secured approximately $16.1 million in proceeds from a public offering, strengthening their balance sheet.
- They have doubled the number of contracts in their concierge medicine program, indicating growth in this area.
- Lucid Diagnostics Inc (LUCD) has a successful partnership with a major health system for a comprehensive esophageal pre-cancer testing program.
- The company is optimistic about imminent Medicare coverage for their Eoguard test, which could significantly boost commercialization efforts.
Negative Points
- Revenue of $800,000 fell short due to external headwinds and a greater concentration of testing through healthcare events.
- There were delays in cash collections from UnitedHealthcare due to a national issue with their new system for molecular pathology claims.
- The quarterly burn rate was $11.3 million, slightly higher than the average for the preceding four quarters.
- The effective average selling price (ASP) declined quarter over quarter, partly due to mix and reimbursement challenges.
- The company faces challenges in securing reimbursement from Kaiser and other insurers, impacting revenue recognition.
